GlobeNewsWire
28 Sept 2026, 12:50 UTC · 1h ago
Verdict
Headline takes no side. We score PALI +0.80 across four claims — strongly bullish.
+0.80strongly bullish
More positive than 88% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish · 3 new · 1 priced in
Palisade Bio will present Phase 1b findings in fibrostenotic Crohn’s disease showing early endoscopic improvement and PDE4 target engagement at UEG Week 2026.
Newpress release dated Sept 28, 2026
So whatPositive Phase 1b data serves as the primary catalyst for the upcoming Phase 2 transition in Q4 2026 or early 2027.
More positive than 79% of claims this week
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
The company will showcase data indicating that PALI-2108 promotes clinical response in ulcerative colitis patients within one week of treatment.
Newpress release dated Sept 28, 2026
More positive than 66% of claims this week
Palisade Bio is developing a transcriptomic biomarker to predict treatment response to PALI-2108 in ulcerative colitis patients.
Newpress release dated Sept 28, 2026
So whatA validated biomarker can increase Phase 2 success rates by allowing for patient enrichment, reducing the risk of trial failure.
More positive than 54% of claims this week
PALI-2108 is currently being advanced into Phase 2 clinical development for both ulcerative colitis and Crohn's disease.
Priced inno timing evidence for this specific status
So whatMoving to Phase 2 typically increases capital expenditure, which may necessitate a secondary offering if cash runway is short.
More positive than 45% of claims this week
Which stocks this story touches
More positive than 88% of ticker scores this week
The company is presenting positive clinical data, including early endoscopic improvement and favorable safety for its lead program PALI-2108.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
4h ago
−0.3%
Price flat so far
$1.45 vs $1.45 close before publication (Sep 25) · not market-adjusted
PALI chart →
